PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 9 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 9 months ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
BRIEF published on 01/13/2025 at 11:31, 1 year 9 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
PRESS RELEASE published on 01/13/2025 at 11:26, 1 year 9 months ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 1 year 10 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
BRIEF published on 12/24/2024 at 20:51, 1 year 10 months ago GenSight Biologics obtient un financement de 1,5 million d'euros auprès d'investisseurs existants Financement Investisseurs Thérapie Génique Mandats GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 10 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 10 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 1,5 million d'euros auprès d'investisseurs existants pour le développement de thérapies géniques innovantes. Perspectives de croissance et objectifs à court terme Croissance Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 11/13/2024 at 07:35, 1 year 11 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
BRIEF published on 11/13/2024 at 07:35, 1 year 11 months ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
Published on 10/28/2026 at 22:35, 8 hours 32 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 18 hours 37 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 18 hours 37 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 18 hours 37 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 18 hours 37 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/29/2026 at 06:55, 11 minutes ago Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
Published on 10/29/2026 at 06:55, 12 minutes ago Alzchem increases sales and profitability in the first nine months of 2026
Published on 10/29/2026 at 06:51, 16 minutes ago KION grows revenue and profitability in the first nine months driven by Intelligent Automation Solutions
Published on 10/29/2026 at 06:30, 36 minutes ago Redcare Pharmacy delivers strong Q3, with revenue increasing 18% driven by Rx and adjusted EBITDA margin up 1.0pp YoY to 3.4%.
Published on 10/29/2026 at 06:30, 36 minutes ago Ad hoc announcement pursuant to Art. 53 LR News Release
Published on 10/28/2026 at 17:56, 13 hours 10 minutes ago OPR - Mise à disposition de l'addendum au rapport d'expertise indépendante
